Deborah N Kalkman1, Tom F Brouwer2, Jim T Vehmeijer2, Wouter R Berger2, Reinoud E Knops2, Robbert J de Winter2, Ron J Peters2, Bert-Jan H van den Born2. 1. Heart Center, Department of Clinical and Experimental Cardiology (D.N.K., T.F.B., J.T.V., W.R.B., R.E.K., R.d.W., R.J.P.), and Department of Vascular Medicine (B.-J.H.v.d.B.), Academic Medical Center, University of Amsterdam, the Netherlands. Heart Center, Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (W.R.B.). d.n.kalkman@amc.uva.nl. 2. Heart Center, Department of Clinical and Experimental Cardiology (D.N.K., T.F.B., J.T.V., W.R.B., R.E.K., R.d.W., R.J.P.), and Department of Vascular Medicine (B.-J.H.v.d.B.), Academic Medical Center, University of Amsterdam, the Netherlands. Heart Center, Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (W.R.B.).
Abstract
BACKGROUND:Low systolic blood pressure (SBP) values are associated with an increased risk of cardiovascular events, giving rise to the so-called J-curve phenomenon. We assessed the association between on-treatment SBP levels, cardiovascular events, and all-cause mortality in patients randomized to different SBP targets. METHODS: Data from 2 large randomized trials that randomly allocated hypertensive patients at high risk for cardiovascular disease to intensive (SBP<120 mm Hg) or conventional (SBP<140 mm Hg) treatment were pooled and harmonized for outcomes and follow-up duration. Using natural cubic splines, we plotted the hazard ratio for all-cause mortality and cardiovascular events against the mean on-treatment SBP per treatment group. RESULTS: The pooled data consisted of 194 875 on-treatment SBP measurements in 13 946 patients (98.9%). During a median follow-up of 3.3 years, cardiovascular events occurred in 1014 patients (7.3%), and 502 patients died (3.7%). For both blood pressure targets, an identical shape of the J curve was present, with a nadir for cardiovascular events and all-cause mortality just below the SBP target. Patients in the lowest SBP stratum were older, had a higher body mass index, smoked more often, and had a higher frequency of diabetes mellitus and cardiovascular events. CONCLUSIONS: Low on-treatment SBP levels are associated with increased cardiovascular events and all-cause mortality. This association is independent of the attained blood pressure level because the J curve aligns with the SBP target. Our results suggest that the benefit or risk associated with intensive blood pressure-lowering treatment can be established only via randomized clinical trials. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01206062 and NCT00000620.
RCT Entities:
BACKGROUND: Low systolic blood pressure (SBP) values are associated with an increased risk of cardiovascular events, giving rise to the so-called J-curve phenomenon. We assessed the association between on-treatment SBP levels, cardiovascular events, and all-cause mortality in patients randomized to different SBP targets. METHODS: Data from 2 large randomized trials that randomly allocated hypertensivepatients at high risk for cardiovascular disease to intensive (SBP<120 mm Hg) or conventional (SBP<140 mm Hg) treatment were pooled and harmonized for outcomes and follow-up duration. Using natural cubic splines, we plotted the hazard ratio for all-cause mortality and cardiovascular events against the mean on-treatment SBP per treatment group. RESULTS: The pooled data consisted of 194 875 on-treatment SBP measurements in 13 946 patients (98.9%). During a median follow-up of 3.3 years, cardiovascular events occurred in 1014 patients (7.3%), and 502 patients died (3.7%). For both blood pressure targets, an identical shape of the J curve was present, with a nadir for cardiovascular events and all-cause mortality just below the SBP target. Patients in the lowest SBP stratum were older, had a higher body mass index, smoked more often, and had a higher frequency of diabetes mellitus and cardiovascular events. CONCLUSIONS: Low on-treatment SBP levels are associated with increased cardiovascular events and all-cause mortality. This association is independent of the attained blood pressure level because the J curve aligns with the SBP target. Our results suggest that the benefit or risk associated with intensive blood pressure-lowering treatment can be established only via randomized clinical trials. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01206062 and NCT00000620.
Authors: Tara I-Hsin Chang; Sai Liu; Medha Airy; Jingbo Niu; Mintu P Turakhia; Jennifer E Flythe; Maria E Montez-Rath; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2019-06-07 Impact factor: 8.237
Authors: Srinivasan Beddhu; Glenn M Chertow; Alfred K Cheung; William C Cushman; Tom Greene; Guo Wei; Robert Boucher; Paul K Whelton Journal: Circulation Date: 2018-06-12 Impact factor: 29.690
Authors: Didier Collard; Tom F Brouwer; Rik H G Olde Engberink; Aeilko H Zwinderman; Liffert Vogt; Bert-Jan H van den Born Journal: Hypertension Date: 2020-03-30 Impact factor: 10.190